Clinical Trials Office The MCC Clinical Trials Office (CTO) provides a full range of research services for all aspects of clinical trials in the Research Programs of the Center. This includes protocol development and preparation, regulatory compliance, quality assurance, data and safety monitoring, research nursing, and study management. It is organized into three divisions, reporting the CTO director, Joanne Mortimer, MD: Study Design and Development, Operations (including Regulatory Affairs, Study Administration and Study. Operations) and Community and Affiliations Liaison. The CTO addresses the needs of clinician scientists in the development and activation of protocols and also functions as an integral part of the health care team in providing state of the art and efficient clinical care to the protocol patient. The CTO has undergone considerable reorganization during the past grant period, with increasing improvement in data quality and accrual to therapeutic trials. As a result of changes, the time required for 1KB approval and contracting has decreased significantly and the quality of data capture has improved. Such improvements have contributed to an increase in patient accruals.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA023100-27S6
Application #
8468778
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
2014-04-30
Budget Start
2011-05-01
Budget End
2013-04-30
Support Year
27
Fiscal Year
2012
Total Cost
$290,834
Indirect Cost
$99,604
Name
University of California San Diego
Department
Type
DUNS #
804355790
City
La Jolla
State
CA
Country
United States
Zip Code
92093
Connor, Michael; Karunamuni, Roshan; McDonald, Carrie et al. (2017) Regional susceptibility to dose-dependent white matter damage after brain radiotherapy. Radiother Oncol 123:209-217
Ly, Peter; Teitz, Levi S; Kim, Dong H et al. (2017) Selective Y centromere inactivation triggers chromosome shattering in micronuclei and repair by non-homologous end joining. Nat Cell Biol 19:68-75
Sundaramoorthy, Sriramkumar; Garcia Badaracco, Adrian; Hirsch, Sophia M et al. (2017) Low Efficiency Upconversion Nanoparticles for High-Resolution Coalignment of Near-Infrared and Visible Light Paths on a Light Microscope. ACS Appl Mater Interfaces 9:7929-7940
D'Antonio, Matteo; Woodruff, Grace; Nathanson, Jason L et al. (2017) High-Throughput and Cost-Effective Characterization of Induced Pluripotent Stem Cells. Stem Cell Reports 8:1101-1111
Guo, Shicheng; Diep, Dinh; Plongthongkum, Nongluk et al. (2017) Identification of methylation haplotype blocks aids in deconvolution of heterogeneous tissue samples and tumor tissue-of-origin mapping from plasma DNA. Nat Genet 49:635-642
Jiang, Qingfei; Crews, Leslie A; Holm, Frida et al. (2017) RNA editing-dependent epitranscriptome diversity in cancer stem cells. Nat Rev Cancer 17:381-392
Krishnan, A P; Karunamuni, R; Leyden, K M et al. (2017) Restriction Spectrum Imaging Improves Risk Stratification in Patients with Glioblastoma. AJNR Am J Neuroradiol 38:882-889
Martínez, María Elena; Gomez, Scarlett L; Tao, Li et al. (2017) Contribution of clinical and socioeconomic factors to differences in breast cancer subtype and mortality between Hispanic and non-Hispanic white women. Breast Cancer Res Treat 166:185-193
Connor, Michael J; Marshall, Deborah C; Moiseenko, Vitali et al. (2017) Adverse Events Involving Radiation Oncology Medical Devices: Comprehensive Analysis of US Food and Drug Administration Data, 1991 to 2015. Int J Radiat Oncol Biol Phys 97:18-26
Panopoulos, Athanasia D; D'Antonio, Matteo; Benaglio, Paola et al. (2017) iPSCORE: A Resource of 222 iPSC Lines Enabling Functional Characterization of Genetic Variation across a Variety of Cell Types. Stem Cell Reports 8:1086-1100

Showing the most recent 10 out of 805 publications